肺癌是我国及世界范围内发病率和死亡率最高的恶性肿瘤之一，非小细胞肺癌（NSCLC）约占肺癌的 85%，1/3 的患者在确诊时已为局部晚期 NSCLC，5 年生存率仅 13% ~ 16%。其中，N2 期肺癌患者预后更差，手术切除后 3 年生存率仅 9% ...

Meanwhile AstraZeneca also saw its shares hit a 52-week high after BMS’s bad news, as its PD-L1 candidate durvalumab (currently ... from filing the drug in lung cancer. Nevertheless, analysts ...

Use the least expensive option of the available treatments (including durvalumab and atezolizumab). Take account of administration costs, dosages, price per dose and commercial arrangements. If the ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab ... limited-stage small cell lung cancer (LS-SCLC).

Imfinzi (durvalumab) was recommended by NICE for NHS use in combination with etoposide plus either carboplatin or cisplatin for adults with untreated extensive-stage small cell lung cancer (ES-SCLC).

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...

AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...

You might have etoposide with either cisplatin or carboplatin. You may have these drugs together with the immunotherapy drugs atezolizumab or durvalumab. Early stage means that the cancer is small and ...

“These NIAGARA data confirm the compelling efficacy of the durvalumab perioperative regimen in muscle-invasive bladder cancer, and importantly, show this regimen improved outcomes regardless of ...